First Interstate Bank increased its stake in shares of Allergan PLC. (NYSE:AGN) by 52.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 977 shares of the company’s stock after buying an additional 336 shares during the period. First Interstate Bank’s holdings in Allergan PLC. were worth $233,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Roundview Capital LLC raised its stake in shares of Allergan PLC. by 71.0% in the first quarter. Roundview Capital LLC now owns 4,527 shares of the company’s stock valued at $1,082,000 after buying an additional 1,880 shares during the last quarter. Steinberg Global Asset Management raised its stake in shares of Allergan PLC. by 38.1% in the first quarter. Steinberg Global Asset Management now owns 11,364 shares of the company’s stock valued at $2,715,000 after buying an additional 3,134 shares during the last quarter. InterOcean Capital LLC raised its stake in shares of Allergan PLC. by 152.8% in the first quarter. InterOcean Capital LLC now owns 9,608 shares of the company’s stock valued at $2,296,000 after buying an additional 5,808 shares during the last quarter. Tredje AP fonden raised its stake in shares of Allergan PLC. by 0.9% in the first quarter. Tredje AP fonden now owns 68,541 shares of the company’s stock valued at $16,376,000 after buying an additional 625 shares during the last quarter. Finally, WFG Advisors LP raised its stake in shares of Allergan PLC. by 4.1% in the first quarter. WFG Advisors LP now owns 656 shares of the company’s stock valued at $157,000 after buying an additional 26 shares during the last quarter. Institutional investors and hedge funds own 84.77% of the company’s stock.

Shares of Allergan PLC. (NYSE:AGN) traded down 0.59% during mid-day trading on Monday, hitting $241.22. 1,515,996 shares of the stock were exchanged. The stock’s 50 day moving average is $245.21 and its 200 day moving average is $237.12. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The firm has a market cap of $81.02 billion, a P/E ratio of 7.52 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the firm posted $3.35 earnings per share. Analysts expect that Allergan PLC. will post $16.20 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.16%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

TRADEMARK VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/07/first-interstate-bank-boosts-stake-in-allergan-plc-nyseagn-updated-updated-updated.html.

Several brokerages have issued reports on AGN. Credit Suisse Group set a $288.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Saturday. Royal Bank Of Canada set a $285.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a research note on Thursday. Wells Fargo & Company lifted their price target on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a research note on Thursday. Mizuho reissued a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a research note on Wednesday, August 2nd. Finally, Deutsche Bank AG reissued a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Seven analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and an average target price of $274.14.

In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.